Xalkori Capsule, Coated Pellets
Product Images NDC 0069-1500

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Xalkori (NDC 0069-1500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Xalkori 01)

Chemical structure of crizotinib, the active ingredient in Xalkori. The structure shows a complex arrangement of rings and atoms including chlorine, fluorine, nitrogen, oxygen, and methyl groups as part of the molecule.*

FDA Label Image

Figure 1 (Xalkori 02)

A Kaplan-Meier progression-free survival probability graph comparing Xalkori (crizotinib) to chemotherapy over time in months. The curve shows higher survival probability for Xalkori patients (median 10.9 months) versus chemotherapy patients (median 7.0 months). The chart includes a hazard ratio of 0.45 with 95% confidence interval and a risk table below showing patient numbers at risk over time for both groups.*

FDA Label Image

Figure 2 (Xalkori 03)

A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time (months) comparing Xalkori (crizotinib) and chemotherapy. The plot includes median survival times, hazard ratio, confidence interval, and p-value, with number at risk table below for both treatment groups.*

FDA Label Image

Logo (Xalkori 04)

FDA Label Image

Logo (Xalkori 05)

FDA Label Image

Figure A (Xalkori 05a)

An illustration showing a hand holding a single Xalkori capsule between the thumb and index finger. The capsule is marked with the Pfizer logo, indicating the manufacturer Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Figure B (Xalkori 05b)

An instructional illustration showing a pair of hands holding a capsule labeled 'Pfizer.' The image demonstrates how to separate the capsule halves by pulling them apart with arrows indicating the direction to open the capsule.*

FDA Label Image

Figure C (Xalkori 05c)

A black and white illustration showing a side profile of a face taking medication from an open capsule labeled Pfizer, with small pellets pouring toward the mouth. The image depicts the administration of oral coated pellet capsules, associated with the Pfizer pharmaceutical brand.*

FDA Label Image

Figure D (Xalkori 05d)

Illustration showing how to open an oral capsule containing coated pellets by emptying the contents into a measuring cup or onto a spoon. The image demonstrates capsule opening and dispensing for oral administration of Xalkori (crizotinib) capsules.*

FDA Label Image

Logo (Xalkori 05e)

FDA Label Image

Principal Display Panel (250 mg Capsule Bottle Label)

Xalkori 250 mg capsules coated pellets label by Pfizer Laboratories Division of Pfizer Inc. The label shows the drug name with generic name crizotinib, dosage strength of 250 mg, and package size containing 60 capsules. Storage instructions indicate room temperature 20° to 25°C with permitted excursions, and dispensing requirements note tight containers and enclosed medication guide. Origin is Made in Ireland.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Xalkori 200 mg capsules containing crizotinib, oral coated pellets in a bottle of 60 capsules. The label states to swallow capsules whole and indicates prescription use only. Manufactured by Pfizer Laboratories Division, Pfizer Inc. The label includes storage instructions, a barcode, and batch information areas.*

FDA Label Image

Principal Display Panel (20 mg Oral Pellets Label)

Xalkori 20 mg oral pellets capsule label from Pfizer Laboratories Division, Pfizer Inc. The label instructs to open the capsule shell to administer pellets and not to swallow the capsule whole or crush or chew the pellets. It indicates the package contains 60 capsules and includes storage information with temperature guidelines from 20°C to 25°C. The label includes a QR code for instructions and displays the NDC 0069-0251-60 and GTIN barcode.*

FDA Label Image

Principal Display Panel (50 mg Oral Pellets Label)

Label for Xalkori (crizotinib) oral pellets, 50 mg strength, by Pfizer Laboratories. The label includes dosing instructions to open the capsule shell to administer pellets without swallowing the capsule whole or chewing pellets. The package contains 60 capsules. Storage instructions specify 20°C to 25°C with permitted excursions from 15°C to 30°C.*

FDA Label Image

Principal Display Panel (150 mg Oral Pellets Label)

Label for Xalkori 150 mg oral pellets capsules by Pfizer Laboratories Div Pfizer Inc. The label instructs to dispense an enclosed medication guide and specifies storage between 20°C to 25°C with allowed excursions. It notes capsules contain 150 mg crizotinib, with 60 capsules in the package, and includes administration instructions to open the capsule shell and not swallow, crush, or chew pellets. The product is made in Ireland.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.